1.Biggar RJ. AIDS incubation in 1891 HIV seroconverters from different exposure groups. AIDS 1990; 4: 1059–66.
2.Chevret S, Costagliola D, Lefrère J et al. , A new approach to estimating AIDS incubation times: results in homosexual infected men. J Epidemiol Comm Health 1992; 46: 582–6.
2.Bacchetti P. Estimating the incubation period of AIDS by comparing population infection and diagnosis patterns. J Am Stat Assoc 1990; 412: 1002–8.
4.Phillips AN, Sabin CA, Elford J et al. , Use of CD4 lymphocyte count to predict long term survival free of AIDS after HIV infection. BMJ 1994; 309: 309–13.
5.Griffiths PD. Studies to define viral cofactors for human immunodeficiency virus. Infect Ag Dis 1992; 1: 237–44.
6.Gendelman HE, Phelps W, Feigenbaum L et al. , Transactivation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Nat Acad Sci USA 1986; 83: 9759–63.
7.Davis MG, Kenney SC, Kamine J et al. , Immediate-early gene region of human cytomegalovirus transactivates the promoter of human immunodeficiency virus. Proc Nat Acad Sci USA 1987; 84: 8642–6.
8.Kenney S, Kamine J, Markovitz D et al. , An Epstein–Barr virus immediate-early gene product transactivates gene expression from the human immunodeficiency virus long terminal repeat. Proc Nat Acad Sci USA 1988; 85: 1652–6.
9.Siddiqui A, Gaynor R, Srinivasan A et al. , Trans-activation of viral enhancers including long terminal repeat of the human immunodeficiency virus by the hepatitis B virus X protein. Virology 1989; 169: 479–84.
10.Moss AR, Bacchetti P, Osmond D et al. , Seropositivity for HIV and the development of AIDS or AIDS-related condition: three-year follow-up of the San Francisco General Hospital Cohort. BMJ 1988; 296: 745–50.
11.Blaxhult A, Granath F, Lidman K et al. , The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS 1990; 4: 125–9.
12.Phillips AN, Lee CA, Elford J et al. , More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991; 4: 970–5.
13.Berry NJ, MacDonald Burns D, Wannamethee G et al. , Serological studies on the acquisition of antibodies to cytomegalovirus, herpes simplex virus and human immunodeficiency virus among general hospital patients and those attending a clinic for sexually transmitted diseases. J Med Virol 1988; 24: 385–93.
14.Griffiths PD, Baboonian C. A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br J Obstet Gynaecol 1984; 91: 307–15.
15.Webster A, Lee CA, Cook DG et al. , Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet 1989; ii: 63–6.
16.Jackson JB, Erice A, Englund JA et al. , Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion 1988; 28: 187–9.
17.Rugman FP, Mannion PT, Hay CR et al. , Cytomegalovirus, serum beta 2 microglobulin and progression to AIDS in HIV-seropositive haemophiliacs. Lancet 1989; ii: 631.
18.Becherer PR, Smiley ML, Matthews TJ et al. , Human immunodeficiency virus-1 disease progression in hemophiliacs. Am J Hem 1990; 34: 204–9.
19.Rabkin CS, Hatzakis A, Griffiths PD et al. , Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus-infected hemophilia patients. J Infect Dis 1993; 168: 1260–3.
20.Lee CA, Phillips AN, Elford J et al. , The natural history of human immunodeficiency virus infection in a haemophilic cohort. Brit J Haematol 1989; 73: 228–34.
21.Phillips AN, Lee CA, Elford J et al. , Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991; 337: 389–92.
22.Bofill M, Janossy G, Lee CA et al. , Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV diganosis. Clin Exp Immunol 1992; 88: 243–52.
23.Berry NJ, Grundy JE, Griffiths PD. Radioimmunoassay for the detection of IgG antibodies to herpes simplex virus and its use as a prognostic indicator of HSV excretion in transplant recipients. J Med Virol 1987; 21: 147–54.
24.Altman DG. Practical statistics for medical research. London, UK: Chapman and Hall, 1991.
25.Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
26.Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
27.SAS Inst Inc. SAS Technical Report P-217. SAS/STAT Software: The PHREG Procedure. Version 6. Cary, NC: 1991.
28.Phillips AN, Elford J, Sabin CA et al. , Immunodeficiency and the risk of death in HIV infection. JAMA 1992; 268: 2662–6.
29.Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (No. RR-17): 1–17
30.Webster A, Grundy JE, Lee CA et al. , Cytomegalovirus infection and progression to AIDS. Lancet 1989; ii: 681.
31.Pillay D, Lipman MCI, Lee CA et al. , A clinico-pathological audit of opportunistic viral infections in HIV-infected patients. AIDS 1993; 7: 969–74.
32.Youle MS, Gazzard BG, Johnson MA et al. , Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994; 8: 641–9.
33.Cooper DA, Pehrson PO, Pedersen C et al. , The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 1993; 7: 197–207.
34.Meyers JD, Reed EC, Shepp DH et al. , Acyclovir for prevention of cytomegalovirus infection and disease after allogenic marrow transplantation. N Engl J Med 1988; 318: 70–5.
35.Balfour HR, Chace BA, Stapleton JT et al. , A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381–7.
36.Prentice HG, Gluckman E, Powles RL et al. , Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749–53.